Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy (PAP_OXT)

Primary objective is to obtain preliminary data on salivary oxytocin reactivity during a single clinical LSD intake administered as part of PAP for refractory anxiety or depression under compassionate-use authorisation.

No interference with routine clinical care: four saliva samples will be collected on the day of dosing and participants will complete routine self-report questionnaires; participants are selected from consecutive patients in the Addiction Department.